Clinical Report: The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors
Overview
This integrative review examines the relationship between physical activity levels and sexual function in breast cancer survivors (BCSs). It highlights a significant gap in literature regarding exercise's impact on sexual health outcomes, despite the prevalence of sexual dysfunction among BCSs.
Background
Breast cancer is a leading cancer diagnosis among women, with a 5-year survival rate of 91%. Many survivors experience sexual dysfunction due to treatment-related changes, which can negatively affect quality of life. Addressing sexual health in BCSs is crucial, yet often overlooked in clinical practice.
Data Highlights
This review synthesizes existing literature on the effects of physical activity on sexual function in BCSs, noting insufficient evidence to support exercise as a remedy for sexual dysfunction.
Key Findings
50% to 70% of women experience unfavorable changes to sexual function post-breast cancer treatment.
30% to 40% of women on tamoxifen report negative sexual experiences.
Over 50% of women on aromatase inhibitors experience loss of sexual well-being.
46% of cancer survivors report unmet sexual health needs, with 71% receiving no medical care for sexual dysfunction.
Current guidelines recommend at least 150 minutes of moderate-intensity aerobic activity weekly for cancer survivors.
There is a lack of modality-specific data on exercise interventions for improving sexual health in BCSs.
Clinical Implications
Healthcare providers should prioritize discussions around sexual health with breast cancer survivors, as many experience significant dysfunction. Incorporating physical activity into survivorship care may improve overall quality of life, though more research is needed to establish its direct effects on sexual function.
Conclusion
The review underscores the need for further investigation into the role of physical activity in enhancing sexual health outcomes for breast cancer survivors, addressing a critical gap in current literature.
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
